Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008 (2008), Article ID 821592, 5 pages
Review Article

PPAR- 𝜶 Ligands as Potential Therapeutic Agents for Wet Age-Related Macular Degeneration

The Wilmer Ophthalmological Institute, School of Medicine, Johns Hopkins University, Baltimore, MD 21287-9278, USA

Received 1 November 2007; Revised 24 January 2008; Accepted 19 February 2008

Academic Editor: Suofu Qin

Copyright © 2008 Marisol del V Cano and Peter L. Gehlbach. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The peroxisome proliferator-activated receptors (PPAR's) are members of the steroid/thyroid nuclear receptor, superfamily of transcription factors. There are currently three known PPAR subtypes, 𝛼 , 𝛽 , and 𝛾 . The PPARs are now recognized participants in a number of biological pathways some of which are implicated in the pathogenesis of age-related macular degeneration (AMD). These include immune modulation, lipid regulation, and oxidant/antioxidant pathways important to the onset and progression of “dry” AMD, and vascular endothelial growth factor (VEGF) mediated pathways that stimulate choroidal neovascularization (CNV), characteristic of “wet” AMD. PPAR- 𝛼 is found in retina and also on vascular cells important to formation of CNV. At this time, however, relatively little is known about potential contributions of PPAR- 𝛼 to the pathogenesis of dry and wet AMD. This review examines current literature for potential roles of PPAR- 𝛼 in the pathogenesis and potential treatment of AMD with emphasis on prevention and treatment of wet AMD.